Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 9;8(2):e000706. doi: 10.1136/jitc-2020-000706

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Tumor-infiltrating lymphocytes (TILs) generated by panning are tumor reactive. (A) Degranulation (CD107a+) of autologous TIL products left unstimulated, OKT3 stimulated or in response to the autologous tumor cell line (auto-TCL). (B) Frequency of degranulation of the final TIL products. (C) Interferon gamma (IFN-γ) expression by autologous TILs in the indicated conditions. (D) Frequency of IFN-γ expression within the final TIL products. (E) Costaining IFN-γ versus CD107a of panning TIL in response to autologous tumor cells. (F) Percentage of CD107a+ and/or IFN-γ+ TIL (tumor-reactive TIL) in the final TIL products. (G) Tumor-reactive TIL yield—calculated by multiplying the percentage of tumor-reactive TIL by the total TIL yield for each condition and sample. FTD, fresh tumor digest; PreREP, Pre-Rapid Expansion Protocol.